Gilead Sciences shares got downgraded by BMO Capital and Wells Fargo analysts.
BMO Capital's Matthew Luchini slashed his rating on the bitotech company’s stock to market perform from outperform. Luchini re-iterated his price target at $79.
While Luchini thinks that Gilead’s anti-COVID-19 drug remdesivir is encouraging, he also mentions "continued uncertainty around the remdesivir commercial opportunity," . That’s what makes him neutral on the shares "ahead of a better entry point."
Wells Fargo analyst Jim Birchenough lowered rating on the stock, to equal-weight from overweight. He maintained his target price, at $87. Birchenough is hopeful about remdesivir being a part of a potential economic recovery from the coronavirus pandemic; but he also feels that there is uncertainty regarding the amount of revenue the drug will generate for Gilead.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GILD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 33 cases where GILD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 70%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 55 cases where GILD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on GILD as a result. In 52 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 164 of 272 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
The 10-day RSI Indicator for GILD moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 23 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 26 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.949) is normal, around the industry mean (19.199). P/E Ratio (17.844) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.025) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor